EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain

David Anderson iD, Moti Ramgopal, Debbie P Hagins, Johnnie Lee, Richard Bruce Simonson, Tien-Huei Hsu, Ping Xu, Nina Ahmad, William R Short iD

Clinical Infectious Diseases · 17.03.2025 · 80 (3) · 602-612

DOI: 10.1093/cid/ciae449 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.09.2024. Verfasst von David Anderson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Vaccines, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors, HIV Protease Inhibitors, Weight Gain. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Scientific Affairs, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Integrase strand transfer inhibitor (INSTI)–based antiretroviral (ARV) therapies have been associated with greater weight gain in people with human immunodeficiency virus (HIV) versus those on protease inhibitor (PI)–based regimens. The DEFINE study investigated whether switching from an INSTI- to a PI-based regimen could mitigate/reverse weight gain.

Methods

DEFINE (NCT04442737) was a randomized, 48-week, open-label, prospective, phase 4 study in virologically suppressed adults with HIV-1 and ≥10% weight gain on INSTI + tenofovir alafenamide (TAF)/emtricitabine (FTC; <36 months prescreening). Participants either switched immediately to darunavir/cobicistat/FTC/TAF (D/C/F/TAF) or continued INSTI + TAF/FTC during weeks 0–24 then switched to D/C/F/TAF for weeks 24–48. The primary endpoint was least squares (LS) mean (95% confidence interval [CI]) percent weight change from baseline to week 24.

Results

Overall, 103 adults were randomized (D/C/F/TAF, n = 53; INSTI + TAF/FTC, n = 50); 30% were female, and 61% were Black/African American. No significant difference in weight change was observed at week 24 (LS mean change: D/C/F/TAF, 0.63% [95% CI, −.44% to 1.70%] vs INSTI + TAF/FTC, −0.24% [95% CI, −1.35% to .87%]; P = .24); however, a trend toward weight loss was observed with extended time post–ARV switch to D/C/F/TAF (baseline to week 48, −0.36% [95% CI, −1.77% to 1.06%]), particularly in subgroups at higher weight gain risk (eg, female and Black/African American participants). Metabolic endpoints paralleled weight change over time. D/C/F/TAF was well tolerated, with comparable virologic efficacy between arms.

Conclusions

While no significant change in body weight was observed at 24 weeks after switching from INSTI + TAF/FTC to D/C/F/TAF among adults with weight gain, a trend toward weight loss emerged with longer time post–ARV switch, supporting further investigation of ARV selection/switch for weight management. Clinical Trials Registration. NCT04442737.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV Integrase InhibitorsHIV Protease InhibitorsWeight GainAdultFemaleHumansMaleMiddle AgedDarunavirEmtricitabineHIV-1Prospective StudiesTenofovirAlanine

Stichwörter der Autor:innen

AntiretroviralHuman immunodefiiciency virusIntegrase strand transfer inhibitorProtease inhibitorWeight

Substanzen

DarunavirEmtricitabineHIV Integrase InhibitorsHIV Protease InhibitorsTenofovirtenofovir alafenamideAlanine

Autor:innen und Institutionen

  • Department of Infectious Diseases and Vaccines, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Department of Medicine, Midway Immunology and Research Center, Fort Pierce, Florida, USA.
  • Chatham CARE Center, Savannah, Georgia, USA.
  • Department of Biostatistics and Decision Sciences, Janssen Research & Development, LLC, Titusville, New Jersey, USA.
  • Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennyslvania, USA.

ORCID-Profile: David Anderson, William R Short

Förderung

  • Janssen Scientific Affairs
  • LLC

Zitieren

APA

Anderson, D., Ramgopal, M., Hagins, D. P., Lee, J., Simonson, R. B., Hsu, T. H., Xu, P., Ahmad, N., & Short, W. R. (2025). DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain. Clinical Infectious Diseases, 80(3), 602-612. https://doi.org/10.1093/cid/ciae449

Vancouver

Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, et al. DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain. Clinical Infectious Diseases. 2025;80(3):602-612. doi:10.1093/cid/ciae449

BibTeX
@article{Anderson2025,
  author = {Anderson, David and Ramgopal, Moti and Hagins, Debbie P and Lee, Johnnie and Simonson, Richard Bruce and Hsu, Tien-Huei and Xu, Ping and Ahmad, Nina and Short, William R},
  title = {DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {3},
  pages = {602--612},
  doi = {10.1093/cid/ciae449}
}
Kostenlos starten →